Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepa...
Q1 2026
May 14, 2026
FY 2025
Feb 26, 2026
Q4 2025
Q3 2025
Nov 4, 2025
Q2 2025
Aug 6, 2025